HER2 gene amplification in breast cancer - A rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations

American Journal of Clinical Pathology

Volumn 137, Issue 4, 2012, Pages 595-605

  Starczynski, Jane ^a,b   Atkey, Neil ^c   Connelly, Yvonne ^d   O'Grady, Tony ^e   Campbell, Fiona M ^f   Di Palma, Silvana ^g   Wencyk, Peter ^h   Jasani, Bharat ^f   Gandy, Michael ⁱ   Bartlett, J M S ^b,j  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^b ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^c SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^d ADELAIDE AND MEATH HOSPITAL   (Ireland)

^e ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^f UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^g UNIVERSITY OF SURREY   (United Kingdom)

^h NOTTINGHAM CITY HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^j WESTERN GENERAL HOSPITAL   (United Kingdom)

more..

Author keywords

Breast cancer; Evidence based reporting; Guidelines; HER2 gene amplification; In situ hybridization; Research

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST BIOPSY; BREAST CANCER; CHROMOSOME 17; CHROMOSOME LOSS; GENE AMPLIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MEDICAL AUDIT; PRACTICE GUIDELINE; PRIORITY JOURNAL; TUMOR CELL; BREAST TUMOR; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; METABOLISM; QUALITY CONTROL; REPRODUCIBILITY;

BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; QUALITY CONTROL; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS;

EID: 84860595433     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPATBZ2JFN1QQC     Document Type: Article

References (15)

1. Sauter G, Lee J, Bartlett JMS, et al.Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009;27:1323-1333.
2. Walker RA, Bartlett JMS, Dowsett M, et al.HER2 testing in the UK: further update to recommendations. J Clin Pathol. 2008;61:818-824. (Pubitemid 351969725)
3. Wolff AC, Hammond ME, Schwartz JN, et al.American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145. (Pubitemid 350003059)
4. Bartlett JMS, Starczynski J, Atkey N, et al.HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods. J Clin Pathol. 2011;64:649-653.
5. Walker RA, Bartlett JMS, Dowsett M, et al.HER2 testing in the UK: further update to recommendations. J Clin Pathol. 2008;61:818-824. (Pubitemid 351969725)
6. Bartlett AI, Starczynski J, Robson T, et al.Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition. Am J Clin Pathol. 2011;136:266-274.
7. Watters AD, Going JJ, Cooke TG, et al.Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat. 2003;77:109-114. (Pubitemid 36197611)
8. Vance GH, Barry TS, Bloom KJ, et al.Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med. 2009;133:611-612.
9. Risio M, Casorzo L, Redana S, et al.HER2 gene-amplified breast cancers with monosomy of chromosome 17 are poorly responsive to trastuzumab-based treatment. Oncol Rep. 2005;13:305-309.
10. Bartlett JMS, Campbell FM, Mallon EA. Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined? Am J Clin Pathol. 2008;130:920-926.
11. Jacobson KK, Morrison LE, Henderson BT, et al.Gene copy mapping of the ERBB2/TOP2A region in breast cancer. Genes Chromosomes Cancer. 2004;40:19-31. (Pubitemid 38524615)
12. Morrison LE, Jewell SS, Usha L, et al.Effects of ERBB2 amplicon size and genomic alterations of chromosomes 1, 3, and 10 on patient response to trastuzumab in metastatic breast cancer. Genes Chromosomes Cancer. 2007;46:397-405. (Pubitemid 46411330)
13. Marchiò C, Lambros MB, Gugliotta P, et al.Does chromosome 17 centromere copy number predict polysomy in breast cancer? a fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol. 2009;219:16-24.
14. Arriola E, Marchio C, Tan DSP, et al.Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Invest. 2008;88:491-503. (Pubitemid 351581454)
15. Tubbs RR, Hicks DG, Cook J, et al.Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 status in adenocarcinoma of the breast: a single institution experience. Diagn Mol Pathol. 2007;16:207-210. (Pubitemid 350196977)